Fibrinolytic status in acute coronary syndromes: Evidence of differences in relation to clinical features and pathophysiological pathways

Summary

Limited data are available on the role of innate fibrinolysis in acute coronary syndromes (ACS). In the present study we evaluated the dynamic alterations of fibrinolytic markers in patients presenting with ACS. Tissue-type-(tPA) and urokinase type-(uPA) plasminogen activators, plasminogen activator inhibitor (PAI-1) antigen and activity and thrombin activatable fibrinolysis inhibitor (TAFI) were analysed in 50 patients with ST elevation myocardial infarction (STEMI), 47 non-STEMI patients (NSTEMI), 40 patients with stable coronary artery disease (CAD) and 39 controls. The parameters were measured on day 1 and days 3, 7 and 30. Counts of monocyte subsets, monocyte-platelet aggregates and plasma inflammatory cytokines were assessed on admission. On day 1, TAFI was higher in NSTEMI vs. STEMI (p<0.001) while PAI-1 activity was higher in STEMI (p<0.001). In STEMI, uPA activity levels was low on day 1 but significantly increased on day 30 (p<0.001). TAFI levels were increased in NSTEMI on day 1 and gradually reduced by day 30 (p<0.05). In STEMI, TAFI levels peaked at day 7 (p<0.05) and dropped significantly by day 30 (p<0.05). CD14++CD16+ monocytes were independently associated with PAI-1 activity in ACS (p=0.03). Monocyte-platelet aggregates rather than platelet-free monocytes were an independent determinant of tPA, PAI-1 antigen and TAFI on a multivariate analysis (p<0.05). There are significant differences in fibrinolytic activity between patients with STEMI and NSTEMI. These changes could reflect the role of these factors in post-MI myocardial healing. Monocyteplatelet interactions are independently associated with the regulation of the fibrinolytic status in ACS.

Note: The editorial process for this article was fully handled by Prof. Christian Weber, Editor-in-Chief.

Keywords

Acute coronary syndromes - fibrinolysis - monocyte-platelet aggregates - monocyte subsets - non-ST-elevation myocardial infarction - ST-elevation myocardial infarction

• References

• 1 Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibri-nolytic system. J Thromb Haemost 2009; 07: 4-13.
• 2 Kilpatrick LM, Harris RL, Owen KA. et al. Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase. Blood 2006; 108: 2616-2623.
• 3 Tkachuk VA, Plekhanova OS, Parfyonova Y V. Regulation of arterial remodeling and angiogenesis by urokinase-type plasminogen activator. Can J Physiol Pharmacol 2009; 87: 231-251.
• 4 Schafer K, Konstantinides S, Riedel C. et al. Different mechanisms of increased luminal stenosis after arterial injury in mice deficient for urokinase- or tissuetype plasminogen activator. Circulation 2002; 106: 1847-1852.
• 5 Marcucci R, Brogi D, Sofi F. et al. PAI-1 and homocysteine, but not lipoprotein (a) and thrombophilic polymorphisms, are independently associated with the occurrence of major adverse cardiac events after successful coronary stenting. Heart 2006; 92: 377-381.
• 6 Sinkovic A, Pogacar V. Risk stratification in patients with unstable angina and/or non-ST-elevation myocardial infarction by Troponin T and plasminogen-activator-inhibitor-1 (PAI-1). Thromb Res 2004; 114: 251-257.
• 7 Sargento L, Saldanha C, Monteiro J. et al. Evidence of prolonged disturbances in the haemostatic, hemorheologic and inflammatory profiles in transmural myocardial infarction survivors. Thromb Haemost 2003; 89: 892-903.
• 8 Thogersen AM, Jansson JH, Boman K. et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98: 2241-2247.
• 9 Juhan-Vague I, Pyke SD, Alessi MC. et al. Fibrinolytic factors and the risk of myo-cardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996; 94: 2057-2063.
• 10 Plouet J, Moro F, Bertagnolli S. et al. Extracellular cleavage of the vascular en-dothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J Biol Chem 1997; 272: 13390-13396.
• 11 Traktuev DO, Tsokolaeva ZI, Shevelev AA. et al. Urokinase gene transfer augments angiogenesis in ischemic skeletal and myocardial muscle. Mol Ther 2007; 15: 1939-1946.
• 12 Zhu Y, Carmeliet P, Fay W P. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 1999; 99: 3050-3055.
• 13 Hoffmeister HM, Jur M, Wendel H P. et al. Alterations of coagulation and fibrino-lytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris. Circulation 1995; 91: 2520-2527.
• 14 Halvorsen S, Huber K. The role of fibrinolysis in the era of primary percutaneous coronary intervention. Thromb Haemost 2011; 105: 390-395.
• 15 Maekawa Y, Anzai T, Yoshikawa T. et al. Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction: a possible role for left ventricular remodeling. J Am Coll Cardiol 2002; 39: 241-246.
• 16 Shantsila E, Lip GY. Monocytes in acute coronary syndromes. Arterioscler Thromb Vasc Biol 2009; 29: 1433-1438.
• 17 Ziegler-Heitbrock L, Ancuta P, Crowe S. et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010; 116: e74-80.
• 18 Shantsila E, Wrigley B, Tapp L. et al. Immunophenotypic characterization of human monocyte subsets: possible implications for cardiovascular disease pathophysiology. J Thromb Haemost 2011; 09: 1056-1066.
• 19 Shantsila E, Lip GY. The role of monocytes in thrombotic disorders. Insights from tissue factor, monocyte-platelet aggregates and novel mechanisms. Thromb Haemost 2009; 102: 916-924.
• 20 Hristov M, Leyendecker T, Schuhmann C. et al. Circulating monocyte subsets and cardiovascular risk factors in coronary artery disease. Thromb Haemost 2010; 104: 412-414.
• 21 Hristov M, Weber C. Differential role of monocyte subsets in atherosclerosis. Thromb Haemost 2011; 106: 757-762.
• 22 Soo KS, Northeast AD, Happerfield LC. et al. Tissue plasminogen activator production by monocytes in venous thrombolysis. J Pathol 1996; 178: 190-194.
• 23 Dejouvencel T, Doeuvre L, Lacroix R. et al. Fibrinolytic cross-talk: a new mechanism for plasmin formation. Blood 2010; 115: 2048-2056.
• 24 Castellote JC, Grau E, Linde MA. et al. Detection of both type 1 and type 2 plasminogen activator inhibitors in human monocytes. Thromb Haemost 1990; 63: 67-71.
• 25 Semeraro F, Ammollo CT, Semeraro N. et al. Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins. Haematologica 2009; 94: 819-826.
• 26 Li n JH, Garand M, Zagorac B. et al. Identification of human thrombin-activatable fibrinolysis inhibitor in vascular and inflammatory cells. Thromb Haemost 2011; 105: 999-1009.
• 27 Mishra N, Vercauteren E, Develter J. et al. Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms. Thromb Haemost 2011; 106: 90-101.
• 28 Schulz C, von Bruhl ML, Barocke V. et al. EMMPRIN (CD147/basigin) mediates platelet-monocyte interactions in vivo and augments monocyte recruitment to the vascular wall. J Thromb Haemost 2011; 09: 1007-1019.
• 29 Bournazos S, Rennie J, Hart S P. et al. Monocyte functional responsiveness after PSGL-1-mediated platelet adhesion is dependent on platelet activation status. Arterioscler Thromb Vasc Biol 2008; 28: 1491-1498.
• 30 Passacquale G, Vamadevan P, Pereira L. et al. Monocyte-platelet interaction induces a pro-inflammatory phenotype in circulating monocytes. PLoS One 2011; 06: e25595.
• 31 da Costa Martins PA, van Gils JM, Mol A. et al. Platelet binding to monocytes increases the adhesive properties of monocytes by up-regulating the expression and functionality of beta1 and beta2 integrins. J Leukoc Biol 2006; 79: 499-507.
• 32 Di Santo A, Amore C, Dell'Elba G. et al. Glycogen synthase kinase-3 negatively regulates tissue factor expression in monocytes interacting with activated platelets. J Thromb Haemost 2011; 09: 1029-1039.
• 33 Yong AS, Pennings GJ, Chang M. et al. Intracoronary shear-related up-regulation of platelet P-selectin and platelet-monocyte aggregation despite the use of aspirin and clopidogrel. Blood 2011; 117: 11-20.
• 34 Furman MI, Barnard MR, Krueger LA. et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 2001; 38: 1002-1006.
• 35 Van de Werf F, Bax J, Betriu A. et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909-2945.
• 36 Niccoli G, Burzotta F, Galiuto L. et al. Myocardial no-reflow in humans. J Am Coll Cardiol 2009; 54: 281-292.
• 37 Kapiotis S, Jilma B, Quehenberger P. et al. Morning hypercoagulability and hy-pofibrinolysis. Diurnal variations in circulating activated factor VII, prothrombin fragment F1+2, and plasmin-plasmin inhibitor complex. Circulation 1997; 96: 19-21.
• 38 Shantsila E, Tapp LD, Wrigley BJ. et al. The effects of exercise and diurnal variation on monocyte subsets and monocyte-platelet aggregates. Eur J Clin Invest. 2012 epub ahead of print.
• 39 Pamukcu B, Lip G Y, Shantsila E. The nuclear factor--kappa B pathway in atherosclerosis: a potential therapeutic target for atherothrombotic vascular disease. Thromb Res 2011; 128: 117-123.
• 40 Minami E, Castellani C, Malchodi L. et al. The role of macrophage-derived uroki-nase plasminogen activator in myocardial infarct repair: urokinase attenuates ventricular remodeling. J Mol Cell Cardiol 2010; 49: 516-524.
• 41 Zhang Y, Zhou ZH, Bugge TH. et al. Urokinase-type plasminogen activator stimulation of monocyte matrix metalloproteinase-1 production is mediated by plasmin-dependent signaling through annexin A2 and inhibited by inactive plasmin. J Immunol 2007; 179: 3297-3304.
• 42 Pineda J, Marin F, Marco P. et al. The prognostic value of biomarkers after a premature myocardial infarction. Int J Cardiol 2010; 143: 249-254.
• 43 Paola Cellai A, Antonucci E, Alessandrello Liotta A. et al. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit. Thromb Res 2006; 118: 495-500.
• 44 Zorio E, Castello R, Falco C. et al. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. Br J Haematol 2003; 122: 958-965.
• 45 Seron M V, Plug T, Marquart JA. et al. Binding characteristics of thrombin-activat-able fibrinolysis inhibitor to streptococcal surface collagen-like proteins A and B. Thromb Haemost 2011; 106: 609-616.
• 46 Tapp LD, Shantsila E, Wrigley BJ. et al. The CD14++CD16+ monocyte subset and monocyte-platelet interactions in patients with ST-elevation myocardial infarction. J Thromb Haemost. 2011 epub ahead of print.